Cargando…

Effectiveness and Treatment Compliance of Salmeterol–Fluticasone Easyhaler(®) Among Patients with Asthma, COPD, or Asthma–COPD Overlap Syndrome: Real-World Study Findings

INTRODUCTION: For inhalation therapies to be effective, it is crucial that patients manage inhaler use correctly in their everyday life and achieve treatment compliance. We investigated the effectiveness of the salmeterol–fluticasone propionate Easyhaler(®) (SF EH) device-metered dry powder inhaler...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tamási, Lilla, Bartha, Anna, Ferencz, Aranka, Tímár, Mihály, Vahteristo, Mikko, Takala, Aino, Müller, Veronika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628494/ https://www.ncbi.nlm.nih.gov/pubmed/36318368 http://dx.doi.org/10.1007/s41030-022-00201-z

Ejemplares similares

A non-interventional switch study in adult patients with asthma or COPD on clinical effectiveness of salmeterol/fluticasone Easyhaler(®) in routine clinical practice
por: Vinge, Ines, et al.
Publicado: (2021)

Characteristics of reversible and nonreversible COPD and asthma and COPD overlap syndrome patients: an analysis of salbutamol Easyhaler data
por: Müller, Veronika, et al.
Publicado: (2016)

Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects
por: Kirjavainen, Merja, et al.
Publicado: (2018)

Consistent Dosing Through the Salmeterol–Fluticasone Propionate Easyhaler for the Management of Asthma and Chronic Obstructive Pulmonary Disease: Robustness Analysis Across the Easyhaler Lifetime
por: Turpeinen, Anni, et al.
Publicado: (2021)

Inhaler Competence and Patient Satisfaction with Easyhaler(®): Results of Two Real-Life Multicentre Studies in Asthma and COPD
por: Gálffy, Gabriella, et al.
Publicado: (2013)

Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD
por: Gao, Jinming, et al.
Publicado: (2015)

Salmeterol/fluticasone combination in the treatment of COPD
por: Chung, K F
Publicado: (2006)

Biochemical Behaviours of Salmeterol/Fluticasone Propionate in Treating Asthma and Chronic Obstructive Pulmonary Diseases (COPD)
por: Mills, Hilla, et al.
Publicado: (2022)

Effectiveness and Patient Satisfaction with Budesonide/Formoterol Easyhaler(®) Among Patients with Asthma or COPD Switching from Previous Treatment: a Real-World Study of Patient-Reported Outcomes
por: Gálffy, Gabriella, et al.
Publicado: (2019)

Impact of Clinical Factors on Generic and Disease-Specific Quality of Life in COPD and Asthma-COPD Overlap with Exacerbations
por: Lázár, Zsófia, et al.
Publicado: (2020)

In Vitro Flow Rate Dependency of Delivered Dose and Fine Particle Dose of Salmeterol/Fluticasone Propionate Easyhaler and Seretide Diskus with Patient Flow Rates Collected in a Randomized Controlled Trial
por: Jõgi, Rain, et al.
Publicado: (2019)

Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
por: Balint, Beatrix, et al.
Publicado: (2010)

The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD
por: Yawn, Barbara P, et al.
Publicado: (2010)

Extrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD
por: Singh, Dave, et al.
Publicado: (2014)

The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device
por: Tashkin, Donald P., et al.
Publicado: (2021)

Phenotype of Asthma-COPD Overlap in COPD and Severe Asthma Cohorts
por: Joo, Hyonsoo, et al.
Publicado: (2022)

Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial
por: Singh, Dave, et al.
Publicado: (2015)

Evaluation of Fluticasone Propionate and Fluticasone Propionate/Salmeterol Combination on Exercise in Pediatric and Adolescent Patients with Asthma
por: Murray, John J, et al.
Publicado: (2011)

Patients with asthma or chronic obstructive pulmonary disease (COPD) can generate sufficient inspiratory flows via Easyhaler(®) dry powder inhaler: a pooled analysis of two randomized controlled trials
por: Malmberg, L. Pekka, et al.
Publicado: (2021)

Fatigue, Depression, and Anxiety in Patients with COPD, Asthma and Asthma-COPD Overlap
por: Homętowska, Henryka, et al.
Publicado: (2022)

Clinically relevant subgroups in COPD and asthma
por: Turner, Alice M., et al.
Publicado: (2015)

Vitamin D deficiency is associated with impaired disease control in asthma–COPD overlap syndrome patients
por: Odler, Balázs, et al.
Publicado: (2015)

Heterogeneity of asthma and COPD overlap
por: Kim, Min-Hye, et al.
Publicado: (2018)

Current trends in the treatment of asthma: focus on the simultaneous administration of salmeterol/fluticasone
por: Teply, Robyn, et al.
Publicado: (2010)

Fluticasone/salmeterol reduces remodelling and neutrophilic inflammation in severe equine asthma
por: Bullone, Michela, et al.
Publicado: (2017)

Cost-effectiveness of combination fluticasone propionate–salmeterol 250/50 μg versus salmeterol in severe COPD patients
por: Dalal, Anand A, et al.
Publicado: (2010)

Sputum cell count: biomarkers in the differentiation of asthma, COPD and asthma–COPD overlap
por: Gao, Jie, et al.
Publicado: (2017)

Health characteristics of patients with asthma, COPD and asthma–COPD overlap in the NHANES database
por: Llanos, Jean-Pierre, et al.
Publicado: (2018)

Coronary heart disease and heart failure in asthma, COPD and asthma-COPD overlap
por: Ingebrigtsen, Truls Sylvan, et al.
Publicado: (2020)

Mucus Plugs and Small Airway Dysfunction in Asthma, COPD, and Asthma-COPD Overlap
por: Tamura, Kanami, et al.
Publicado: (2022)

Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma
por: Houghton, Catherine M, et al.
Publicado: (2007)

COPD assessment test and severity of airflow limitation in patients with asthma, COPD, and asthma–COPD overlap syndrome
por: Kurashima, Kazuyoshi, et al.
Publicado: (2016)

Heterogeneity of asthma–COPD overlap syndrome
por: Joo, Hyonsoo, et al.
Publicado: (2017)

Risk of Malignancy in Patients with Asthma-COPD Overlap Compared to Patients with COPD without Asthma
por: Bonnesen, Barbara, et al.
Publicado: (2022)

LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD
por: Zhong, Nanshan, et al.
Publicado: (2015)

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
por: Anzueto, Antonio R, et al.
Publicado: (2017)

Comparison of pulmonary function in patients with COPD, asthma-COPD overlap syndrome, and asthma with airflow limitation
por: Kitaguchi, Yoshiaki, et al.
Publicado: (2016)

Importance of fractional exhaled nitric oxide in the differentiation of asthma–COPD overlap syndrome, asthma, and COPD
por: Chen, Feng-jia, et al.
Publicado: (2016)

Differential DAMP release was observed in the sputum of COPD, asthma and asthma-COPD overlap (ACO) patients
por: Huang, Xiaolin, et al.
Publicado: (2019)

The comparison of fluticasone propionate/formoterol with fluticasone propionate/salmeterol for paediatric asthma: a meta-analysis of randomized controlled trials
por: Jin, Xiaofen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2c1l8kugu1kd5chgch7sg2rtlk